BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-80@pharmaconomics
DTSTAMP:20260707T034115Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:LLY Phase 3 — Tirzepatide (estimated date)
DESCRIPTION:Phase 3 trial results for Tirzepatide in Type 1 Diabetes are due ~ Nov 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06962280\n\nTrack it: https://www.pharmaconomics.com/e/80
URL:https://www.pharmaconomics.com/e/80
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:LLY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR